BAMF
SUPN icon

BI Asset Management Fondsmaeglerselskab’s Supernus Pharmaceuticals SUPN Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,390
Closed -$46K – 901
2025
Q1 		$46K Buy
+1,390
New +$49.3K ﹤0.01% 817

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's SUPN Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 1,390 shares — an estimated $46K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in SUPN in Q1 2025 and held it in 1 quarter. The position peaked at $46K in Q1 2025. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 1,390 Supernus Pharmaceuticals shares in Q2 2025, an estimated $46K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Supernus Pharmaceuticals position peaked at $46K in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.